Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane Evaluates 2 Advanced Hodgkin Lymphoma Regimens

Cochrane; 2017 May 25; Skoetz, Will, Monsef, et al

Publish date:: May 31, 2017

First-line chemotherapy with escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) can improve survival in patients with early unfavorable and advanced stage Hodgkin lymphoma, according to a Cochrane review of 5 studies involving more than 3,400 individuals.

The studies compared BEACOPP with doxorubicin, bleomycin, vinblastine, dacarbazine. Among the findings:

Patients who were given chemotherapy that included BEACOPP escalated experienced better overall survival.
They also had a better chance of avoiding tumor recurrence.
There was no difference in treatment-related mortality between the 2 regimens.
Patients receiving BEACOPP were at higher risk of secondary acute myeloid leukemia and myelodysplastic syndromes.
BEACOPP escalated tended to cause more adverse events such as anemia, neutropenia, thrombocytopenia and infections.
Quality of life was not assessed in the evaluated trials.

Citation:

Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews. 2017, Issue 5. Art. No.: CD007941. doi:10.1002/14651858.CD007941.pub3.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9